MedTrace Logo

Elimination of VPB With Ablation Versus Anti-arrhythmic Drug Treatment

NCT03845010 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2023-06-28

No results posted yet for this study

Summary

The ECTOPIA trial is a randomized, multicenter, clinical trial to assess elimination of ventricular premature beats (VPB) with catheter ablation versus optimal anti-arrhythmic drugs (AAD) treatment with flecainide/verapamil or sotalol.

Conditions

  • Ventricular Premature Beats

Interventions

DRUG

Sotalol

Patients will be titrated to the maximal tolerated dose of sotalol with a targeted dose of 80 thrice daily (TID)

DRUG

Flecainide and verapamil

Patients will receive maximal tolerated dose of flecainide and verapamil with titration to a maximal dose of 200 mg of flecainide and 240 mg of verapamil per day

PROCEDURE

Catheter ablation

Patients will undergo VPB/VT ablation using a percutaneous transfemoral approach according to standard clinical routine

Sponsors & Collaborators

  • Maatschap Cardiologie Zwolle

    lead OTHER

Principal Investigators

  • Arif Elvan, MD, PhD · Isala

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
76 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-12
Primary Completion
2023-01-17
Completion
2023-01-17

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03845010 on ClinicalTrials.gov